Submission of Outcome of Board Meeting.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts more than Nifty Microcap 250 and 2.7 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Novelix Pharmaceuticals' board approved the unaudited financial results for Q3 FY26 (quarter ended December 31, 2025). Total income stood at Rs. 484.03 lakhs, up sharply from Rs. 53.01 lakhs in the same quarter last year. Net profit for the quarter was Rs. 100.44 lakhs versus Rs. 14.79 lakhs in Q3 FY25, while the 9-month net profit reached Rs. 164.46 lakhs compared with a loss of Rs. 7.65 lakhs in the same period last year. The board also approved the allotment of 23,20,000 equity shares at Rs. 60 each (face value Rs. 10, premium Rs. 50) via preferential issue to promoter group and non-promoter investors, raising Rs. 13.92 crore. The paid-up equity capital rose from Rs. 17.615 crore to Rs. 19.935 crore. The auditor (CVS Balachandra Rao & Co) issued an unqualified limited review report.
Massive year-on-year revenue and profit growth signals a strong operational turnaround, which is positive for shareholders. However, the preferential allotment to the promoter group and 35 other allottees at Rs. 60/share will dilute existing shareholders by roughly 13% and brings in fresh capital that may be used for business expansion.